Serum complement levels and the relation between zinc and Age-Related Macular Degeneration.
- Conditions
- AMDMacular Degeneration1004706010027665
- Registration Number
- NL-OMON35087
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 51
• Men and women >= 50 years of age.
• AMD patients previously included in the EUGENDA database.
• Previously genotyped for Y402H (rs1061170) gene variation (from EUGENDA
database).
• Patients with extensive small drusen, intermediate drusen, large drusen, advanced
neovascular AMD without neovascular activity in one or both eyes or geographic
atropy in one or both eyes.
• Informed consent.
• Active leakage from CNV due to AMD.
• Ongoing anti/VEGF treatment.
• Ongoing infection.
• Subretinal hemorrhages.
• History of any vitreous hemorrage within 12 weeks.
• Other ocular disorders that may confound the interpretation of the study results.
• Systemic or local steroid treatment within the last three months.
• Use of any antibiotica.
• Prolonged use of diuretics.
• Supplemental use of iron (38-65 mg/day of elemental iron).
• Use of zink and vitamin supplements one month prior to the study.
• Systhemic diseases that may influence complement levels (atypical haemolytic
uraemic syndrome (aHUS), membranoproliferative glomerulonephritis type 2 (MG2)).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is the serum level of activation fragment C3d and<br /><br>complement component C3, C3d/C3 ratio will be calculated. This ratio is the<br /><br>activity marker of alternative complement pathway. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary outcome is the correlation between this supposed drop in serum<br /><br>level C3d and Y402H polymorphism status in CFH.</p><br>